These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22384167)

  • 1. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
    Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
    Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
    McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
    Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
    Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
    Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
    Zhang WM; Xiao G; Zhang M; Guo AL; Dong Y; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2005 Apr; 34(4):202-5. PubMed ID: 16091172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
    Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
    Vaughan HA; Svobodova S; Macgregor D; Sturrock S; Jungbluth AA; Browning J; Davis ID; Parente P; Chen YT; Stockert E; St Clair F; Old LJ; Cebon J
    Clin Cancer Res; 2004 Dec; 10(24):8396-404. PubMed ID: 15623618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
    Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L
    Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
    Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
    PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.
    Dyrskjøt L; Zieger K; Kissow Lildal T; Reinert T; Gruselle O; Coche T; Borre M; Ørntoft TF
    Br J Cancer; 2012 Jun; 107(1):116-22. PubMed ID: 22596240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
    de Carvalho F; Vettore AL; Inaoka RJ; Karia B; Andrade VC; Gnjatic S; Jungbluth AA; Colleoni GW
    Cancer Immun; 2011 Jan; 11():1. PubMed ID: 21247062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.